Fruquintinib plus sintilimab in previously bevacizumab-treated, pMMR/MSS refractory metastatic colorectal cancer: a phase 2 clinical trial
Fruquintinib plus sintilimab showed promising activity and good tolerability in refractory pMMR/MSS mCRC. Liver metastasis was a negative predictor for efficacy and PFS, especially when combined with the ECOG score. Higher baseline albumin and lower NLR predicted longer OS.
Authors
- Tielong Liu (ORCID: https://orcid.org/0009-0001-5500-4338)
- Ai-Ping. Zhou
- Yulin Sun (ORCID: https://orcid.org/0000-0001-5232-710X)
- Z. Jiang
- Lin Yang (ORCID: https://orcid.org/0000-0002-1981-5977)
- Caifeng Gong (ORCID: https://orcid.org/0000-0002-1864-8206)
- Yuxian Bai (ORCID: https://orcid.org/0000-0002-5004-7523)
- Y. Xin
- Wen Zhang (ORCID: https://orcid.org/0000-0002-3247-9672)
- Jing Huang (ORCID: https://orcid.org/0000-0002-2167-8385)
- Wang Qu (ORCID: https://orcid.org/0000-0002-5997-4761)
- Feilong Zhao
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- National Cancer Center (US)
- Shanghai Medical Information Center (CN)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1007/s00262-025-04237-3
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Chinese Academy of Medical Sciences
- National Science and Technology Major Project
- Cancer Foundation of China